Cover Image
市場調查報告書

特發性肺纖維化 (IPF):流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析

Idiopathic Pulmonary Fibrosis Forecast and Market Analysis for 2035

出版商 Datamonitor Healthcare 商品編碼 365208
出版日期 內容資訊 英文 166 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
特發性肺纖維化 (IPF):流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析 Idiopathic Pulmonary Fibrosis Forecast and Market Analysis for 2035
出版日期: 2017年11月17日 內容資訊: 英文 166 Pages
簡介

2014年10月,FDA同時承認了Esbriet及Ofev作為美國第一個特發性肺纖維化 (IPF) 治療藥。

本報告提供特發性肺纖維化 (IPF) 治療藥趨勢調查,市場定義和概要,疾病定義與診斷,目前治療選擇,處方趨勢,已上市產品簡介,開發後期的開發平台趨勢等彙整資料。

預測:特發性肺纖維化 (IPF)

  • 摘要整理
  • 市場概要、趨勢
  • 調查手法、市場定義
  • Esbriet (pirfenidone)
  • Ofev (nintedanib)
  • 一次調查技術

治療方法:特發性肺纖維化 (IPF)

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢

流行病學:美國、日本、歐盟5國的特發性肺纖維化 (IPF)

  • 摘要整理
  • 資訊來源、分析方法
  • 預測
  • 流行病學者的見解
  • 優勢、規定

上市藥:特發性肺纖維化 (IPF)

  • 摘要整理
  • 產品概要
  • 產品簡介:Esbriet
  • 產品簡介:Ofev

開發平台:特發性肺纖維化 (IPF)

  • 摘要整理
  • 臨床實驗平台概要
  • 標靶治療藥簡介
  • 臨床試驗設計
  • 產品簡介 (開發後期):FG-3019
  • 產品簡介 (開發後期):PRM-151

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC12770

Disease Overview:

Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease in which scarring and thickening of the lung tissue occurs due to unknown causes. In turn, this fibrosis reduces the ability of alveoli to transport oxygen from the lungs to the bloodstream, and results in symptoms such as dyspnea, chronic dry cough, fatigue, and weight loss. While lung function and capacity steadily decline in most IPF patients, some experience a sudden, rapid increase in irreversible disease progression called acute exacerbation. The prognosis of patients with IPF remains poor as those who are ineligible for lung transplantation have few effective treatment options.

Market Snapshot:

  • The size of the IPF market is set to expand significantly due to the growth of Esbriet and Ofev in the US.
  • Treatment of IPF is evolving as mounting evidence and revised international guidelines support clinical decision-making.
  • By 2035, Datamonitor Healthcare estimates that approximately 101,060 cases of IPF will be diagnosed annually in these markets. As IPF disproportionately affects the elderly, aging populations in these markets will be responsible for the largest increases in IPF.
  • Safety and efficacy of Esbriet and Ofev are comparable, but a few small advantages will help Esbriet remain the market-leading therapy.
  • The design of clinical trials continues to standardize as pipeline drugs seek to reverse disease progression.

TABLE OF CONTENTS

FORECAST: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)

  • EXECUTIVE SUMMARY
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: ESBRIET
  • PRODUCT PROFILE: OFEV

TREATMENT: IDIOPATHIC PULMONARY FIBROSIS (Published on 06 November 2017)

  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: IDIOPATHIC PULMONARY FIBROSIS (Published on 10 February 2016)

  • EXECUTIVE SUMMARY
  • SOURCES AND METHODOLOGY
  • FORECAST
  • EPIDEMIOLOGIST INSIGHT
  • STRENGTHS AND LIMITATIONS

MARKETED DRUGS: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)

  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ESBRIET
  • PRODUCT PROFILE: OFEV

PIPELINE: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)

  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • PRODUCT PROFILE (LATE STAGE): GLPG1690
  • PRODUCT PROFILE (LATE STAGE): PBI-4050
  • PRODUCT PROFILE (LATE STAGE): PRM-151
  • PRODUCT PROFILE (LATE STAGE): PAMREVLUMAB

LIST OF FIGURES

  • Figure 1: Idiopathic pulmonary fibrosis - current and future market dynamics analysis
  • Figure 35: Datamonitor Healthcare's drug assessment summary of pamrevlumab for idiopathic pulmonary fibrosis
  • Figure 3: Idiopathic pulmonary fibrosis drug sales across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 4: Total sales categorized by severity across the US, Japan, and five major EU markets, 2016-25
  • Figure 5: Patient-based forecast methodology for idiopathic pulmonary fibrosis
  • Figure 6: Price sources and calculations, by country
  • Figure 7: Esbriet for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 8: Datamonitor Healthcare's drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
  • Figure 9: Datamonitor Healthcare's drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
  • Figure 10: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 11: Ofev for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 1: Cystic fibrosis drug sales across the US and five major EU markets, by country, 2016-25
  • Figure 2: Growth dynamics of the cystic fibrosis market in the US and five major EU markets, by country, 2016-25
  • Figure 14: Distribution of diagnosed idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by severity and country (%)
  • Figure 15: Estimated percentage of idiopathic pulmonary fibrosis patients in each severity who remain undiagnosed across the US, Japan, and five major EU markets
  • Figure 16: Estimated percentage of IPF patients who experience acute exacerbation in the US, Japan, and five major EU markets, by severity and country
  • Figure 17: Overview of the ATS/ERS/JRS/ALAT evidence-based guidelines for the treatment of idiopathic pulmonary fibrosis
  • Figure 18: Percentage of IPF patients who fall into each treatment category in the US, Japan, and five major EU markets, by severity and country
  • Figure 19: Top five pharmacological treatment regimens used in mild IPF patients across the US, Japan, and five major EU markets, by country
  • Figure 20: Top five pharmacological treatment regimens used in moderate IPF patients across the US, Japan, and five major EU markets, by country
  • Figure 2: Leading cystic fibrosis brand sales across the US and five major EU markets, 2016-25
  • Figure 22: Use of Esbriet and Ofev, whether alone or in a combination, across the US, Japan, and five major EU markets, by severity and country
  • Figure 23: Percentage use of Esbriet and Ofev as monotherapy and in each combination across the US, Japan, and five major EU markets, by severity
  • Figure 24: Patients who receive supplemental anti-gastroesophageal reflux medications across the US, Japan, and five major EU markets, by severity and country (%)
  • Figure 25: Non-pharmacological treatments used in mild idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
  • Figure 26: Non-pharmacological treatments used in moderate idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
  • Figure 27: Non-pharmacological treatments used in severe idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
  • Figure 2: Methodology flow for Datamonitor Healthcare's cystic fibrosis patient-based forecast
  • Figure 29: Gender-specific diagnosed incident cases of idiopathic pulmonary fibrosis in the US, Japan, and five major EU markets, by country, 2015
  • Figure 30: Growth in diagnosed prevalent cases of idiopathic pulmonary fibrosis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 31: Esbriet for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 3: Bronchitol sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 33: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 34: Ofev for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 35: Datamonitor Healthcare's drug assessment summary of Ofev for idiopathic pulmonary fibrosis
  • Figure 4: Kalydeco sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 4: Orkambi sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 38: Datamonitor Healthcare's drug assessment summary of GLPG1690 for idiopathic pulmonary fibrosis
  • Figure 39: PBI-4050 for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 40: Datamonitor Healthcare's drug assessment summary of PBI-4050 for idiopathic pulmonary fibrosis
  • Figure 5: Quinsair sales for cystic fibrosis across the five major EU markets, by country, 2016-25
  • Figure 42: Datamonitor Healthcare's drug assessment summary of PRM-151 for idiopathic pulmonary fibrosis
  • Figure 43: Datamonitor Healthcare's drug assessment summary of PRM-151 for idiopathic pulmonary fibrosis
  • Figure 6: Tobi/Tobi Podhaler sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Table 1: Summary of drug classes and molecules included in Datamonitor Healthcare's idiopathic pulmonary fibrosis patientbased forecast
  • Table 2: Exchange rates used for calculating prices
  • Table 3: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
  • Table 4: Esbriet drug profile
  • Table 5: Esbriet Phase III data in idiopathic pulmonary fibrosis
  • Table 6: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 7: Ofev drug profile
  • Table 8: Ofev pivotal trial data in idiopathic pulmonary fibrosis
  • Table 9: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 10: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
  • Table 11: Subtypes of idiopathic interstitial pneumonias
  • Table 12: Datamonitor Healthcare's definition of idiopathic pulmonary fibrosis severity
  • Table 13: Estimated percentage of idiopathic pulmonary fibrosis patients in each severity who remain undiagnosed across the US, Japan, and five major EU markets
  • Table 14: Approved treatments available for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
  • Table 15: Off-label therapies used in the treatment of idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
  • Table 16: Non-pharmacological therapies used in the treatment of idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
  • Table 17: Pharmacological treatment regimens used in mild idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
  • Table 18: Pharmacological treatment regimens used in severe idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
  • Table 19: Sources used for idiopathic pulmonary fibrosis data in the US, Japan, and five major EU markets
  • Table 20: Diagnosed incident cases of idiopathic pulmonary fibrosis in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 21: Age-specific diagnosed incident cases of idiopathic pulmonary fibrosis in the US, Japan, and five major EU markets, by country, 2015
  • Table 22: Diagnosed prevalent cases of idiopathic pulmonary fibrosis in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 23: Age-specific diagnosed prevalent cases of idiopathic pulmonary fibrosis in the US, Japan, and five major EU markets, by country, 2015
  • Table 24: Profiled key marketed drugs for idiopathic pulmonary fibrosis
  • Table 25: Esbriet drug profile
  • Table 26: Esbriet Phase III data in idiopathic pulmonary fibrosis
  • Table 27: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 28: Ofev drug profile
  • Table 29: Ofev pivotal trial data in idiopathic pulmonary fibrosis
  • Table 30: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 31: Phase II pipeline products in development for idiopathic pulmonary fibrosis
  • Table 32: GLPG1690 drug profile
  • Table 33: GLPG1690 Phase II data in idiopathic pulmonary fibrosis
  • Table 34: PBI-4050 drug profile
  • Table 35: PBI-4050 Phase II data in idiopathic pulmonary fibrosis
  • Table 36: PRM-151 drug profile
  • Table 37: PRM-151 Phase II trial in idiopathic pulmonary fibrosis
  • Table 38: PRM-151 Phase I data in idiopathic pulmonary fibrosis
  • Table 39: Pamrevlumab drug profile
  • Table 40: Pamrevlumab Phase II data in idiopathic pulmonary fibrosis
Back to Top